Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Tracy Batchelor MD
Closed to Accrual
To determine if the addition of cediranib to chemoradiation treatment enhances treatment efficacy as measured by the 6-month progression-free survival rate.
Data for this trial is being collected via the NRG/RTOG Data Center.
Histopathologically confirmed glioblastoma (WHO Grade IV) confirmed by central review prior to Step 2 registration. Tumor tissue that is determined by central pathology review prior to Step 2 registration to be of sufficient size for analysis of MGMT status. The tumor must have a supratentorial component.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.